-
Federal Authorities Investigating Suspected Fraud in Fen-phen Class Action Settlement
Some Claimants’ Lawyers May Have Submitted Bogus Heart-damage Claims The U.S. Attorney’s Office in Philadelphia and the FBI are investigating allegations of fraud in the $5 billion fen-phen class action settlement. The federal investigators…
-
Two Key FDA Officials Tell IOM Panel About Their Concerns Over Current Drug-safety System
Lack Of Authority for FDA to Evaluate Safety of Drugs After Marketing Approval On June 8, 2005 Steven K. Galson, acting director of FDA’s Center for Drug Evaluation and Research (CDER), and Janet Woodcock,…
-
Will Merck Settle Some of the Vioxx Cases, or Is This True Hardball?
Can Merck’s Lawyers Defend Against Each of the Thousands of Vioxx Cases? Alex Berenson, of the New York Times ("NYT"), reported that in an August 25, 2005 interview Merck’s general counsel Kenneth C. Frazier…
-
Drug Companies Object to Early Warnings on New FDA “Drug Watch” Site
Will the FDA be Steadfast in Showdown with Big Pharma Over Drug Watch Plan? The FDA intends to post emerging drug-safety concerns that are being evaluated by the agency on a new "Drug Watch"…
-
Vioxx: Merck Has No Plans for a Global Settlement Says General Counsel Frazier
Merck Will Continue to Fight Each Vioxx Lawsuit, Including Humeston Case in NJ Merck & Co.’s General Counsel Kenneth Frazier reiterated in the first part of September 2005 that Merck has no interest in…
-
Propulsid: Blockbuster Drug With Danger Signals That Were Ignored
FDA’s Failure to Act in 1998 Foreshadowed Its Later Mishandling of Vioxx and Bextra A June 2005 article in The New York Times ("NYT") by Gardiner Harris and Eric Koli provided insight about how…
